This study examines the potential use of α-enolase (ENO1) as a potential biomarker and shows that it is highly expressed in bone marrow biopsies from patients with both MDS and AML, and that patients with these diseases also have decreased circulating levels of autoantibodies to ENO1. This evidence concerns the gene ENO1 and acute myeloid leukemia.